• Publications
  • Influence
Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new
Small changes in tumor size or density on CT are sensitive and specific methods of assessing the response of GISTs, and the prognostic value of the proposed CT response criteria should be employed in future studies of patients with GIST. Expand
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine
This trial confirms the effectiveness of imatinib as primary systemic therapy for patients with incurable GIST but did not show any advantage to higher dose treatment. Expand
CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings.
Although subjective evaluation was a better indicator of treatment response than was tumor density alone, the tumor density measurement is a good indicator and provides a reliable quantitative means of monitoring the tumor. Expand
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.
Multiple doses of rhuMAb VEGF were well tolerated, and pharmacokinetic studies indicate that doses of > or = 0.3 mg/kg have a half-life similar to that of other humanized antibodies. Expand
We should desist using RECIST, at least in GIST.
Choi response criteria are reproducible, more sensitive, and more precise than RECIST in assessing the response of GISTs to imatinib mesylate and should be incorporated routinely into future studies of Gist therapy. Expand
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.
The GIST Task Force met for the first time in October 2003 and again in December 2006 with the purpose of expanding on the existing NCCN guidelines for gastrointestinal sarcomas and identifying areas of future research to optimize the understanding and treatment of GIST. Expand
Extraskeletal osteosarcoma. A clinicopathologic review of 26 cases
The clinical records and histopathologic features in 26 cases of extraskeletal osteosarcoma diagnosed at M. D. Anderson Cancer Center (Houston) between 1950 and 1987 were reviewed, finding that tumor size was the main prognostic factor and Histologic pattern and other clinicopathy features did not significantly affect outcome. Expand
Prognostic factors for patients with localized soft‐tissue sarcoma treated with conservation surgery and radiation therapy
Prognostic factors for patients with soft‐tissue sarcoma who are treated with conservative surgery and radiation are documented poorly.
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study
There was evidence of improved response rates for patients with exon 9-mutant tumors treated with imatinib 800 mg versus 400 mg and novel but rare mutations of the KIT extracellular domain (exons 8 and 9) were identified. Expand
Alveolar soft part sarcoma
Routine intracranial imaging is recommended as part of the staging evaluation in all patients who present with alveolar soft part sarcoma. Expand